Study to evaluate the safety and efficacy of Elagolix in Combination with Combined Oral Contraceptives in premenopausal women with documented Endometriosis and associated moderate to severe pain. For premenopausal females 18-49 years of age/not pregnant or planning to become pregnant/documented diagnosis of endometriosis by visualization (eg. laparoscopy or laparotomy)/among other criteria.

This study is for adults, 55 and older OR 18 and older with an additional risk factor, who are showing 1 or more symptoms of Covid-19 within the last 48 hours. It is a study to assess the safety and efficacy of monoclonal antibody VIR-7831 for the early treatment of coronavirus disease 2019 (COVID-19) in non-hospitalized patients.

A study to evaluate the clinical benefit of using hereditary cancer genomic diagnostics to assess overall hereditary genetic cancer risk profile to help guide physicians to pursue preventative measures, which may lead to early detection and treatment of the condition.

A study to evaluate the safety and efficacy of a prospective US radiofrequency device, Viveve, for stress urinary incontinence.

HPV Enriched: Women who are 25 years of age or older undergoing colposcopy based on routine cervical cancer screening (PAP) which has included HR HPV testing within 12 weeks preceding the colposcopy visit. Subject has not had a hysterectomy and is not currently pregnant or planning to become pregnant in the near future. Subjects that participated in the HPV Screening study are not eligible for HPV Enriched.

Intranasal live vaccine for children 6-18 months of age to protect against RSV. Subjects will receive 2 vaccines 56 days apart. This study is double blind placebo controlled for generally healthy infants. Parents must be willing to withhold daycare for 28 days post vaccination.

Driven Covid Test: The Driven FlowTM COVID-19 Antigen Test is a rapid covid test intended for diagnosing SARS-CoV-2 with nasal mid-turbinate swab specimens collected from individuals who are suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset. Subjects will be 5 years of age or older and exhibiting two or more symptoms for COVID-19 illness.

A whey protein based infant formula study to determine tolerance in babies who are reported very to extremely fussy by parents. Subjects must be enrolled between 7 and 65 days old, strictly formula fed and in general good health.

A 2 year study of infant formula and toddler drink to determine tolerability and growth. Participants must enrolled between 0 and 14 days old and be strictly formula fed.

This study collects a blood sample to develop a breast cancer biomarker test. Subjects need to be between 30 and 75 years old.

A 2nd arm of this study is for Subjects needing additional imaging.

A 3rd arm fo this study is for Subjects needing a breast biopsy.